The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

SGN-B6A
An investigational antibody-drug conjugate directed to integrin beta-6

**Target: Integrin beta-6**
- Cell surface receptor involved in solid tumor pathogenesis and invasiveness\(^1\,2\)
- Prevalent expression in HNSCC, ESCC, NSCLC, cSCC, colorectal, gastric, breast, and cervical cancers\(^3\,9\)
- A negative prognostic marker in solid tumors\(^10\)

**Proposed Mechanism of Action\(^11\,14\),\(^a\)**
- Direct cytotoxicity
- Bystander effect
- Immunogenic cell death


\(^{a}\)Based on preclinical data

Proposed Mechanism of Action\(^1, 5, a\)

1. Binds to integrin beta-6
2. Complex internalization and trafficking
3. MMAE release
4. Microtubule disruption
5. Cell cycle arrest and apoptotic cell death

MMAE: monomethyl auristatin E

\(^a\)Based on preclinical data
\(^1\)Additional mechanisms of action and their potential to complement the direct cytotoxicity of some MMAE-based antibody-drug conjugates are currently under investigation.


Clinical Trials

RECRUITING SGNB6A-001: Advanced solid tumors (NCT04389632) SGN-B6A


The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.